Washington Trust Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Washington Trust Bank’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-16	Closed	-$1K	–	716
2016 Q4	$1K	Sell	16 -10	-38%	-$860	﹤0.01%	740
2016 Q3	$2K	Buy	+26	New	+$2.45K	﹤0.01%	700
2015 Q4	–	Sell	-50	Closed	-$5K	–	735
2015 Q3	$5K	Hold	50	–	–	﹤0.01%	669
2015 Q2	$7K	Hold	50	–	–	﹤0.01%	695
2015 Q1	$6K	Hold	50	–	–	﹤0.01%	713
2014 Q4	$5K	Hold	50	–	–	﹤0.01%	772
2014 Q3	$4K	Hold	50	–	–	﹤0.01%	751
2014 Q2	$3K	Hold	50	–	–	﹤0.01%	816
2014 Q1	$3K	Buy	+50	New	+$3.69K	﹤0.01%	772

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Washington Trust Bank's BMRN Position: Q1 2017 in Review

Washington Trust Bank sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 16 shares — an estimated $1K sold.

Washington Trust Bank first reported a position in BMRN in Q1 2014 and held it in 9 quarters. The position peaked at $7K in Q2 2015. 417 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

Washington Trust Bank reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Washington Trust Bank sold 16 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $1K.
Washington Trust Bank first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 9 quarters.
Washington Trust Bank's BioMarin Pharmaceuticals position peaked at $7K in Q2 2015.
417 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Washington Trust Bank's 13F filing for Q1 2017, filed 18 Apr 2017.